Venetolax with Azacitidine Drains Fuel from AML Stem Cells.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30609400.
- Also identified by DOI 10.1016/j.stem.2018.12.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In Nature Medicine, Pollyea et al. (2018) recently reported a remarkable overall response of newly diagnosed elderly acute myeloid leukemia patients to a venetoclax and azacitidine combination in a new clinical trial. This treatment reduced succinate dehydrogenase glutathionylation, impaired the tricarboxylic acid cycle, and depleted ATP in leukemia stem cells.
Medical subject headings
- Azacitidine
- Leukemia, Myeloid, Acute